Incentives for R&D
Key Reports on Ways to Fund the Antibiotic Ecosystem
- 2014: Eastern Research Group for the US Department of Health and Human Services: link
- 2015: Chatham House in London: link
- 2016: UK AMR Review led by Lord Jim O’Neill: link
- 2017: Duke-Margolis Center for Health Policy (11): link
- 2018: DRIVE-AB for the European Union: link
- 2020: United States Government Accountability Office: link
- 2021: EU-JAMRAI-sponsored survey (link to 11 Dec 2020 white paper) of interest in incentives by policymakers in 13 countries (10 from EU plus Canada, South Africa, and Japan)
- Japan, various dates: Multiple documents from the Japanese Pharmaceutical Manufacturers Association (JPMA) on the need for Pull incentives (link) as well as calls for Pull incentives in the report from the Nikkei FT 7th Communicable Diseases Conference (6 Nov 2020).
Newsletters about value, incentives, and funding
- 11 Jan 2021 (link): “All-In Cost Of A New Antibiotic From Discovery To 10 Years On Market” — An integrated update on everything we know at present about the real cost ($ and time) bringing a new antibiotic to market and keeping it there.
- 9 Dec 2020 (link): “Global Survey Of Novel Antibiotic Reimbursement Models / PASTEUR Act Introduced To US House.” — In parallel with PASTEUR moving from the Senate to the House, a WHO-based group has authored an excellent review of global efforts to find new ways to reimburse for the full value of antibiotics.
- 28 Nov 2020 (link): “Global AMR Action: EU Pharmaceutical Strategy; One Health Global Leaders Group On AMR” — EU has announced a pharmaceutical strategy that includes a specific call for “… new incentives to develop antimicrobials as well as new pricing systems.” The strategy also includes a call to create an EU Health Emergency Response Authority (HERA) that sounds very much like BARDA!
- 21 Oct 2020 (link): “Nature Outlook: Antimicrobial Resistance.” — As a supplement to Nature, this superb collection of brief outlook papers (2-4 pages each) provides a concise survey of pretty much everything relevant to the AMR problem: broken economics, new approaches to discovery, use of antibiotics in fish farming, and more. If you only have time for one paper, look at “No money for new drugs” by Plackett (link).
- 30 Sep 2020 (link): “PASTEUR Act (re)introduced: A delinked Pull award advances in the US!” — This is huge deal: bipartisan legislation that would create predictable subscription-based market entry rewards for new antibiotics.
- 9 July 2020 (link): “AMR Action Fund: A $1b Down Payment From Industry; A Call For Creation Of Strong Pull Incentives” — The announcement of the AMR Action Fund is the beginning of the next step towards a stable ecosystem for antibiotics!
- 12 June 2020 (link): “Perspectives on restoring the antibiotic ecosystem: ACS ID, June 2020 issue” — This newsletter surveys the excellent series of papers on AMR R&D in the June 2020 issue of ACS Infectious Diseases.
- 7 June 2020 (link): “Assessing antibiotic value: DTR, fire extinguishers, and a view from Australia” — This newsletter begins with a very succinct summary of the problem with antibiotics.
- 14 Apr 2020 (link): “Pull Incentives For Antibiotics: How Much And Why? — A literature survey” — A summary of papers approaching value from the diverse view points of scientific features at baseline, features that emerge, top-down value estimates, and bottom-up value estimates.
- 29 Mar 2020 (link, plus link to follow-up FAQ): “UK Antibiotic Subscription Pilot Implies Pull Incentive Of Up To $4b”
- 23 Mar 2020 (link): “Tetraphase Sold For $14m … And $600m Goes Up In Smoke!”
- 6 Mar 2020 (link): “What Does An Antibiotic Cost To Develop? What Is It Worth? How To Afford It?”
- 11 Jan 2020 (link): “Japan’s Antibacterial R&D Landscape / Japan Calls For Pull Incentives”
- 5 Jan 2020 (link and link, a 2-part series): “Melinta Goes Bankrupt / Never Let A Good Crisis Go To Waste” — Note that part 2 of this series contains the best estimate to date of the post-approval costs incurred by an antibiotic developer.
- 22 Apr 2019 (link and link, a 2-part series): “Scary, Scarier, Scariest: Achaogen bankruptcy”
- 17 Feb 2019 (link): “Modeling The Value Of An Effective Antibiotic: Megiddo et al.”
- 23 Jan 2018 (link): “Push! Pull! Push! Pull! / Highlights From Davos 2018”
- 11 Sep 2017 (link): “Incentives For Antibiotics: Summary of the insights from DRIVE-AB”
- 8 June 2017 (link): “Ardal et al. / Pull Incentives For Antibiotics – TATFAR Analysis Of 6 Models”the
Dear All, For those of you who enjoy listening to learn, here are some updates to recent newsletters that you might enjoy: 9 Jan 2021 (newsletter): “All-In Cost of a New Antibiotic From Discovery to 10 Years on Market“ As you’ll recall, the key point is that the all-in cost is ~$1.7b per new molecule after
Dear All, JPIAMR is today launching an international call entitled “One Health interventions to prevent or reduce the development and transmission of AMR.” The call, with financial support from the European Commission, includes 30 funding organisations from 21 JPIAMR member countries and has a total estimated call budget of 24.9 million Euro. Here’s the description of